BOULDER, Colo. & TEES VALLEY, England--(BUSINESS WIRE)--BaroFold, Inc., developers of PreEMT™ protein processing technology, and Avecia Biologics Limited have entered into an agreement for process development and cGMP manufacture of BaroFold’s lead, proprietary compound, BaroFeron™, interferon beta-1b. Interferon betas are used as therapeutic agents in the treatment of multiple sclerosis and other autoimmune disorders. The program involves Avecia integrating operation of PreEMT™ technology alongside other stages of protein purification in both pilot and cGMP facilities. Avecia has both installed a PreEMT™ Plus system in its development laboratory and completed manufacture of BaroFeron™.
